Wrap up interview: From LEADERS FREE to clinical practice: a case-based approach in tailoring stent treatment to patients and their bleeding risk


Discussants: Didier Carrié, Gert Richart, Philip Urban
The challenge of high bleeding risk (HBR) patients remains daunting in interventional cardiology, especially in light of the demands for extended dual antiplatelet therapy (DAPT). Could a new polymer-free, drug-eluting stent designed to elute it’s drug rapidly offer a solution for treating these complex patients? The LEADERS FREE trial compared HBR patients treated with either this new active stent or bare metal stents - and both groups received only 30 days of DAPT! What were the results? Join P. Urban, D. Carrié and G. Richardt to find out…